Centrose receives $160K for anti-cancer program

Madison, Wis. - A Centrose, LLC research program designed to improve anti-cancer drugs has received an additional $160,000 in funding from the National Cancer Institute.

Centrose, a Madison-based biopharmaceutical company, will use the funding to further develop sugar enhancement chemistry that reduces the toxic effects and increases the potency of anti-cancer drugs.

Earlier this year, the company licensed a set of drug improvement technologies that use sugars to improve the efficacy of drugs. One project that is partially funded by the new grant is studying whether sugar-enhanced drugs can play a role in the treatment of non-small cell lung cancer, an aggressive form of cancer that is linked to about 80 percent of lung cancer deaths.

Related story

• Centrose lands $875K, seeks $3 million in total capital